Listing of OPKO Health-Branded Personal Health & Wellness Products Including the First-of-Their-Kind Veterinary Care Products in China , Expected in the First Quarter of 2025, Dramatically Expanding the Company's Ongoing e-Commerce Program COCONUT GROVE, Fla. , Dec. 10, 2024 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global e-Commerce provider, today announced a significant expansion... Read More

MIAMI, Nov. 20, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Piper Sandler 36 th Annual Healthcare Conference, being held December 3-5, 2024 at the Lotte New York Palace Hotel in New York City. Management will be holding one-on-one meetings with investors and will be participating in a fireside chat on Wednesday, December 4 th at 1:30 p.m. Eastern time.... Read More

OPKO Healthcare's Veterinary Care Products to be Introduced at Asia's Largest Health and Nutrition Tradeshow Company Invited to Present at Special Event Hosted by U.S. Consulate General During the Expo COCONUT GROVE, Fla. , Nov. 18, 2024 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global e-commerce provider, today announced that it is participating in the 2024 China International... Read More

Company Sees Initial Sales Momentum in China for OPKO Health Products as it Prepares for the Launch of its Florida Sunshine Brand of Vitamins and Supplements COCONUT GROVE, Fla. , Nov. 14, 2024 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global e-Commerce provider, today announced results for its third fiscal quarter ended September 30, 2024 which includes the consolidation of the... Read More

MIAMI, Nov. 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and nine months ended September 30, 2024. Highlights from the third quarter of 2024 and recent weeks include the following: Completed sale of select assets of BioReference Health to Labcorp for $237.5 million . OPKO completed the sale of BioReference Health’s laboratory testing businesses... Read More

MIAMI, Oct. 29, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2024 after the close of the U.S. financial markets on Thursday, November 7, 2024. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on November 7 th... Read More

Company to Support the Sales and Marketing of OPKO's Products on Additional E-Commerce Platforms and on Social Media Channels in China and into the Large Japanese Health and Wellness Market COCONUT GROVE, Fla. and MIAMI , Oct. 7, 2024 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global... Read More

Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of up to $205 million if all options are executed Development work is based on ModeX proprietary MSTAR technology that incorporates multiple antibody binding sites into a single molecule WESTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ:... Read More

WESTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ: OPK) company, today announced the appointment of Giovanni Abbadessa, M.D., Ph.D. as Chief Medical Officer, a newly created position. Dr. Abbadessa has over two decades of experience in drug development, including most recently as Vice President at Sanofi, where he provided executive leadership for advancing oncology... Read More

MIAMI, Aug. 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2024. Highlights from the second quarter and recent weeks include the following: Enrollment underway in the MDX2001 Phase 1 trial for the treatment of solid tumor cancers. MDX2001 , a tetraspecific antibody, is designed to optimize T-cell function to stimulate... Read More

MIAMI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2024 after the close of the U.S. financial markets on Wednesday, August 7, 2024. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on August 7 th beginning at... Read More

MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized the repurchase of up to $100 million of shares of the Company's common stock. Under the repurchase program, OPKO may repurchase shares of its common stock from time to time through open market purchases, block trades, privately negotiated transactions, accelerated share repurchase transactions... Read More

MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces it has entered into a $250 million non-dilutive note purchase agreement with HealthCare Royalty (HCRx) secured by OPKO’s profit share payments from Pfizer received pursuant to its license agreement relating to NGENLA ™ , a once-weekly treatment currently marketed to treat pediatric growth hormone deficiency. “This transaction with HCRx allows... Read More

New Marketing Partner to Support the Expanded Sales of OPKO-Branded Products Throughout China on Additional E-Commerce Platforms, in Brick-and-Mortar Retail Locations and Launch In-Country Digital Marketing Programs COCONUT GROVE, Fla. , July 2, 2024 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global e-Commerce provider, today announced that it has expanded its e-commerce development... Read More

MIAMI, May 31, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Global Healthcare Conference, being held June 4-6, 2024 at the Marriott Marquis in New York City. Management will be holding one-on-one meetings with investors and will be participating in a fireside discussion on Thursday, June 6 th at 10:30 a.m. Eastern time. The fireside chat will... Read More

MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2024. First quarter business highlights include the following: Entered into an agreement with Labcorp to sell select assets of BioReference Health. The transaction includes the sale of BioReference Health’s laboratory testing businesses focused on clinical diagnostics... Read More

MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Tuesday, May 7, 2024. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on May 7 th beginning at 4:30 p.m.... Read More

Transaction to enhance Labcorp's laboratory services network and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI , March 28, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today that they have entered into... Read More

Study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans Candidate showed similar half-life to standard monoclonal antibodies and minimal anti-drug antibodies WESTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced results from a Phase 1 clinical study of SAR441236, its... Read More

New Health and Wellness E-Commerce Storefront Launches After Receiving All Required Approvals with Initial Selection of OPKO Health Products COCONUT GROVE, Fla. , Feb. 28, 2024 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global e-Commerce provider, today announced that its exclusive OPKO Health-branded storefront on Alibaba Group Holding Limited's ("Alibaba")(NYSE: BABA) Tmall Global... Read More

MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023. Business highlights from the fourth quarter and subsequent weeks included the following: ModeX advanced its antiviral and immune-oncology product pipeline. ModeX advanced its pipeline of antiviral and immune-oncology programs utilizing its... Read More

MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial markets on Tuesday, February 27, 2024. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on February 27 th... Read More

E-Commerce Storefront to Initially Support Sales of up to 40 Personal Health and Wellness Products; Final International Certifications and Approvals Required for Formal Launch Expected This Quarter COCONUT GROVE, Fla. , Feb. 5, 2024 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global e-Commerce provider, is preparing for the launch of its exclusive OPKO Health-branded storefront on... Read More

MIAMI, Jan. 09, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (the “Company”) today announced the closing of its previously announced private offering of $230.0 million aggregate principal amount of its Convertible Senior Notes due 2029 (the “Notes”), which amount includes the full exercise of the initial purchaser’s option to purchase an additional $30.0 million aggregate principal amount of the Notes. The Notes... Read More

MIAMI, Jan. 08, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 42 nd Annual J.P. Morgan Healthcare Conference, being held January 8-11, 2024 at Westin St. Francis hotel in San Francisco. Management will be hosting one-on-one meetings with investors and will be presenting on Wednesday, January 10 th at 3:45 p.m. Pacific time. The presentation will be... Read More

MIAMI, Jan. 04, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (the “Company”) today announced the pricing of its private offering of $200.0 million aggregate principal amount of its Convertible Senior Notes due 2029 (the “Notes”). The Company granted the initial purchaser in the offering an option to purchase, within the 13-day period beginning on, and including, the date on which the Notes are first issued, up to... Read More

MIAMI, Jan. 03, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (the “Company”) today announced that it is commencing a private offering of $200.0 million aggregate principal amount of its Convertible Senior Notes due 2029 (the “Notes”). The Company also expects to grant the initial purchaser in the offering an option to purchase, within the 13-day period beginning on, and including, the date on which the Notes are... Read More

ELMWOOD PARK, N.J. , Nov. 28, 2023 /PRNewswire/ -- BioReference ® Health, LLC (BRH), a leading specialty laboratory in the United States , announced a strategic collaboration with Prognos Health, a pioneer in providing accessible, quality real world data ("RWD") for the pharmaceutical and life science industries. This collaborative arrangement will offer healthcare providers and researchers unique solutions to inform... Read More

MIAMI, Nov. 06, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and nine months ended September 30, 2023. Business highlights from the third quarter and subsequent weeks included the following: ModeX Therapeutics Inc. (ModeX) was awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA) to develop novel multispecific... Read More

MIAMI, Nov. 02, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) presented late-breaking clinical data on RAYALDEE ® extended-release calcifediol (ERC) at the American Society of Nephrology (ASN) Kidney Week in Philadelphia today. These data, presented in a poster titled “Control of Secondary Hyperparathyroidism with Extended-release Calcifediol is Associated with Slower CKD Progression” (#TH-PO1152), indicate that... Read More

MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2023 after the close of the U.S. financial markets on Monday, November 6, 2023. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on November 6 th... Read More

MIAMI, Oct. 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) will present late-breaking clinical data on RAYALDEE® extended-release calcifediol (ERC) at the American Society of Nephrology (ASN) Kidney Week in Philadelphia on Thursday, November 2, 2023. These data will be presented in a poster, “Control of Secondary Hyperparathyroidism with Extended-release Calcifediol is Associated with Slower CKD Progression”... Read More

NATICK, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. company (NASDAQ: OPK), has been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services (HHS), to advance a platform and specific candidates designed to address a range of... Read More

MIAMI, Aug. 03, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2023. Second quarter business highlights included the following: U.S. FDA approved NGENLA™ for pediatric growth hormone deficiency; OPKO earned a $90 million milestone payment from its commercial partner, Pfizer. In June 2023, the U.S. Food and Drug... Read More

MIAMI, July 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2023 after the close of the U.S. financial markets on Thursday, August 3, 2023. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on August 3 rd beginning at... Read More

MIAMI, May 03, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2023. First quarter business highlights include the following: OPKO Health’s ModeX Therapeutics, Inc. (ModeX) entered into an exclusive worldwide license and collaboration agreement with Merck to develop MDX-2201 for Epstein-Barr virus. Under the terms of the... Read More

MIAMI, April 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2023 after the close of the U.S. financial markets on Wednesday, May 3, 2023. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on May 3 rd beginning at 4:30 p.m.... Read More

MIAMI, March 09, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that it will hold an R&D Day event on March 20, 2023 beginning at 4:00 p.m. Eastern time. The two-hour virtual event will provide an opportunity to hear from OPKO executives about the ModeX Therapeutics multispecific technology platforms and applications in oncology and infectious diseases. Management will also review the MDX-2201... Read More

MDX-2201 leverages ModeX’s innovative biologics platform to target multiple Epstein-Barr virus (EBV) proteins EBV is the leading cause of infectious mononucleosis and is also associated with some specific types of cancer MIAMI, March 08, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that ModeX Therapeutics, Inc., an OPKO Health company, entered into an exclusive worldwide license and collaboration... Read More

MIAMI, Feb. 23, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended December 31, 2022. Business highlights include the following: Sales are underway by Pfizer for NGENLA® (somatrogon) in 15 countries including Japan, Germany and the United Kingdom; Pfizer expects to launch in all priority ex-U.S. markets by year-end and is continuing to work... Read More

MIAMI, Feb. 16, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2022 after the close of the U.S. financial markets on Thursday, February 23, 2023. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on February 23 rd beginning at... Read More

CINtec ® PLUS Cytology offered as a reflex test when cytology is NILM and HPV positive ELMWOOD PARK, N.J. , Feb. 9, 2023 /PRNewswire/ -- BioReference® Health LLC , one of the largest full-service specialty laboratories in the United States , announced today it will be one of the first commercial laboratories to use offer the CINtec® PLUS Cytology test from Roche Diagnostics. CINtec PLUS Cytology is the only FDA-approved... Read More

MIAMI, Jan. 03, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 41 st Annual J.P. Morgan Healthcare Conference being held January 9-12, 2023 at the Westin St. Francis in San Francisco. Management will be hosting one-on-one meetings with investors and will be presenting on Wednesday, January 11 th at 4:30 p.m. Pacific time. The presentation will be webcast... Read More